Adial Pharmaceuticals (ADIL) Cash from Investing Activities (2021 - 2025)

Adial Pharmaceuticals (ADIL) posted Cash from Investing Activities of $150000.0 for Q3 2025, little changed sequentially from $150000.0 in Q1 2025.

Adial Pharmaceuticals (ADIL) Cash from Investing Activities (2021 - 2025) Analysis & Trends

Adial Pharmaceuticals has reported Cash from Investing Activities for 3 years, with the latest figure at $150000.0 in Q3 2025.

Quarterly Cash from Investing Activities changed N/A year-over-year to $150000.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $650000.0 (changed N/A YoY) and the FY2025 annual result came in at $150000.0, changed N/A from the prior year.
Cash from Investing Activities steadied at $150000.0 in Q3 2025 per ADIL's latest filing, from $150000.0 in the prior quarter.
Over five years, Cash from Investing Activities peaked at $350000.0 in Q3 2023 and troughed at -$33730.0 in Q2 2021.
A 3-year average of $160997.3 and a median of $150000.0 in 2025 frame the typical range for Cash from Investing Activities.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash from Investing Activities (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-45.80 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-92.70 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	329.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-49.35 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-363.46 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-3.17 Bn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	24.51 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-229.72 Mn
10	Adial Pharmaceuticals	29.02 Mn	29.02 Mn	-	-

Download Data